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The exact mechanisms of Adenoid hypertrophy (AHT) pathogenesis and otitis media 
with effusion (OME) are unclear but there is increasing evidence that allergies may play a 
role. We aimed to investigate the prevalence of atopy and the effect of anti-allergic drugs in 
patients with AHT and OME.  
In a non-randomized, prospective cross-sectional study, 122 patients younger than 18 
years of age with AHT or OME were included. Atopic patients based on clinical symptoms 
of allergic disorders and/or elevated levels of total serum immunoglobulin E (IgE) were 
referred to allergists and tested for allergen sensitization by skin prick test (SPT). Atopic 
patients were treated with nasal corticosteroids and antihistamines. Response to treatment 
was evaluated by comparing symptoms score before and after the treatment.  
In this study 122 patients were evaluated, 116 of them had AHT and 30 patients had 
OME. The mean age of participants was 6.7±2.4 years old and 68 of them (55.7%) were 
male. Allergic symptoms were observed in 38 patients with AHT (32.7%) and nine patients 
with OME (30%). Among the total cases, 34 patients (28%) were considered atopic. SPT 
was performed on 25 (73%) cases of atopic patients, with 11 (44 %) positive results. The 
mean symptom score of AHT and OME decreased significantly after treatment respectively, 
(p=0.001, p=0.007).  
According to this study, atopy was relatively common in patients with AHT and OME. 
Treatment with nasal corticosteroid and antihistamines were effective in these patients. 
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INTRODUCTION 
 
Adenoid hypertrophy (AHT) and otitis media with 
effusion (OME) are common otolaryngologic disorders 
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which affect respectively 19% to 70% and 4.5% to 
9.86% of children and adolescent.
1-3
 AHT can cause 
symptoms and complications due to airway 
obstruction.
1,4
 OME can cause symptoms and 
complications like otalgia and conductive hearing 
loss.
3,4
 By understanding the pathogenesis of AHT and 
OME, it would be possible to choose alternative 
nonsurgical treatments and avoid surgical 
complications. AHT and OME pathogenesis seems to 
be multifactorial which includes upper respiratory 
infections, passive smoking, feeding habits, and 
allergy. The exact mechanism by which allergies cause 
AHT and OME are not clear. Adenoid hypertrophy and 
Eustachian tube dysfunction are probably induced by 
chronic inflammation due to contact with allergens.5-11 
This survey aimed to evaluate the relationship between 
AHT, OME, and allergy in preoperational patients. The 
secondary goal of this study was to investigate the 
response of atopic patients to anti-allergic treatment 
with nasal corticosteroid and antihistamine. 
 
MATERIALS AND METHODS 
 
In a non-randomized, prospective, cross-sectional 
study, 122 children less than 18 years old who were 
waiting for adenoidectomy due to AHT and ventilation 
tube placement due to OME were enrolled in. The 
criteria for AHT were chronic nasal obstruction 
symptoms for at least six months and an obstructed 
nasopharyngeal airway by adenoid tissue on lateral 
neck x-ray (more than 0.75 adenoidal-nasopharyngeal 
ratios).
12
 The criteria for OME were: middle ear 
effusion persisting for at least three months 
documented by otoscopy examination which was 
unresponsive to treatment with appropriate antibiotics, 
conductive hearing loss in audiometry, and middle ear 
pressure less than -150 mm H2O in tympanometry.13 
Patients were excluded from the study if they had an 
anatomical deformity in head and neck (i.e., cleft 
palate), upper airway infections in the last 2 weeks, had 
taken nasal or systemic steroid in the previous 2 
months, had undergone adenoidectomy previously, 
systemic disease and a known case of immune 
deficiency and Down syndrome.  
The study was undertaken in an academic tertiary 
care center, otorhinolaryngology department, Shahid 
Sadoughi hospital, Yazd, Iran between September 2007 
and June 2008. The institutional ethics committee 
approved the study (approved number: 17/1/118115). 
Informed consent was obtained from the patients and 
their parents for participation. At study enrollment, 
patients’ demographic, medical history, and symptom 
characteristics were collected. The symptom 
questionnaire consisted of a parental assessment of 
their child's symptoms. Adenoid hypertrophy 
Symptoms (mouth breathing, nasal obstruction, snoring 
and apnea) were scored as; 0=absent/none, 
1=periodic/sometimes, 2=often/most of the time 
3=continuous/all of the time.
14 
The OME symptoms (ear pain, ear fullness or 
discomfort, vertigo or imbalance, and hearing 
impairment) were scored as 0=No problem, 1=Hardly a 
problem, 2=Moderate problem, and 3=Extreme 
problem.13 One milliliter of clotted blood was drawn 
from all patients to evaluate the total immunoglobulin 
E (IgE) antibody level.  
After data collection from patients, patients who 
were atopic according to their clinical history 
(including atopic dermatitis, allergic rhinitis, and 
asthma) and paraclinical data (total IgE serum level 
more than normal level proportional to their age) were 
referred to an allergist. Referred patients were 
evaluated for allergen sensitization by SPT. SPTs were 
performed to common food and aeroallergens in the 
study region with commercial solutions (Stallergenes, 
Antony, France). All tests were performed with 
histamine chloride as positive and 0.9% sodium 
chloride as the negative control. A wheal diameter of 3 
mm more than the negative control was considered as a 
positive answer. Atopic patients undertook nasal 
corticosteroid (fluticasone propionate, 50 mcg/spray) 
one spray per nostril once daily every morning, and a 
second-generation antihistamine (Loratadine or 
Cetirizine) orally at bedtime. The efficacy of treatment 
was assessed by comparing the mean symptom score of 
AHT and OME before and after treatment. 
 
Statistical Analysis 
The data were analyzed using SPSS software 
version 18 (SPSS Inc., Chicago, IL, USA). Baseline 
characteristic of all patients was analyzed using the t-
test. The primary outcome variable was the adenoid 
hypertrophy and the OME symptoms score. Baseline 
and after treatment scores of the two groups were 
compared using the wilcoxon test. The chi-square test 
was used to evaluate the relationship between 
qualitative variables. A p-value of less than 0.05 was 
considered statistically significant for all analysis. 
Allergy and Adenoid Hypertrophy 
Vol. 19, No. 5, October 2020                                                                                                                                                    Iran J Allergy Asthma Immunol, / 531 
Published by Tehran University of Medical Sciences (http://ijaai.tums.ac.ir) 
RESULTS 
 
In this study, 122 patients with AHT and OME 
were included. The mean±SD age of patients was 
6.7±2.4 years and 68 (55.7%) of patients were male.  
Among the 122 patients under survey, 116 had 
AHT and 30 had OME. The prevalence of allergic 
disorders in patients with AHT and OME is shown in 
Figure1. In total, 38 (32.76%) patients with AHT and 9 
(30%) patients with OME had allergic disorders. 
In patients under the study, 30 patients (24.6%) had 
higher IgE levels proportional to their age while in the 
other 92 patients (75.4%) IgE levels were reported to 
be normal. The mean± SD IgE Level was 156±94 
IU/mL. Among the patients with adenoid hypertrophy 
and elevated IgE, 78% have clinical allergic symptoms. 
While in other with normal IgE, 19% were reported to 
have clinical allergic symptoms. A higher IgE level 
was found in AHT patients with allergic symptoms 
(p<0.001).  
The frequency of atopy diagnosed by history and 
elevated IgE level (proportional to their age) was 28% 
(34/122) in the study group. The patients with atopy 
(34 patients) were asked to take the SPT. Twenty-five 
patients agreed to take the SPT. Among the 25 patients, 
all of them had clinical signs of allergy, and seventeen 
patients (68%) had higher levels of IgE. Allergen 
sensitization was reported in 11 of 25 patients (44%) 
who agreed to take SPT. The most common allergens 
to which patient's sensitivity was found were 
categorized as below: 
Russian thistle: 8 (32%), Tree mix: 7 (28%), 
Mugwort: 5 (20%), Mite mix: 5 (20%), Grass mix 5 
(20%), Cockroach: 3 (12%) and Egg 2 (8%). 
The mean ± SD AHT and OME symptom score 
decreased significantly from 8.72± 1.31 and 7.22± 1.39 
before treatment to 4.22 and 4.11 after treatment 
(p=0.001, p=0.007); respectively.  
Response to treatment (defined as a reduction in 
symptom score of more than 50%) in patients with 
allergen sensitization (according to SPT test) was 
significantly higher than patients without allergen 
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Figure 1. Prevalence of allergic disorders in patients with Adenoid Hypertrophy (AHT) and Otitis Media  













Figure 2. Relationship between skin prick test results (SPT) and response to treatment 
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The role of allergy in OME has been evaluated in 
several studies.7,11 In a study by Tomonaga et al, 50% 
(out of 259) of the patients with OME were reported to 
have allergic rhinitis while 21 % of 650 patients, 
subjected to allergic rhinitis were found with OME.
11
 
In comparison, the reported rates in our study were 
23.3% and 18% respectively.  Among different studies 
the incidence of allergy, according to clinical 
symptoms in children with OME varied from less than 
5% to more than 80%.7,11 In our study, the association 
of OME with allergic disorders was 30%.  
The implication of allergy in adenoid hypertrophy 
has also been examined in several studies.
5,8
 In a survey 
conducted by Moderzynski et al, 32.95% of 134 
patients with allergic rhinitis were subjected to AHT.
8
 
In another study conducted by Sadeghi Shabestari et al, 
from 111 patients with AHT, 25.2% presented a history 
of cutaneous allergy and 29.7% a history of respiratory 
allergy.
9
 In a study by Mohamed Yonis et al, from the 
50 patients with AHT, 74% had allergic disorders. 
Interestingly, there was a significant negative 




In our study, the prevalence of allergic rhinitis was 
28.5% in the patients with AHT and OME, while the 
prevalence of atopic dermatitis and asthma was much 
lower (equivalent to 2.5% and 1.7%), respectively. the 
prevalence of allergic diseases in patients with AHT 
and OME, in our study, were similar to the study of 
Sadeghi Shabestari et al and was less than Mohamed 
Yonis's et al study.
5,9
 Different results can be due to 
differences in race, sample size, defined criteria for 
allergic disorders, inclusion and exclusion criteria of 
the study, and other unknown factors.  
In a study performed by Karaca et al, 82 patients 
with symptoms of upper airway obstruction were 
assessed for allergen sensitization by SPT. All patients 
were sensitized to at least one of the tested allergens.10 
In the Sadeghi Shabestari's et al study, a positive skin 
prick test was reported in 70.3% of children with AHT, 
compared with 10% in the control group.
9
 In the study 
by Mohamed Yonis et al, 78% of 50 patients under 
study were sensitized to at least one allergen. 
Unexpectedly, sensitization to house dust mite and 
cotton dust showed a significant negative association 
with the volume of adenoid.5 A positive skin prick test 
in our study was recorded in 11 of the total 25 (44 %) 
patients with atopy who accepted to take a prick test. 
The prevalence of allergen sensitization in our study 
was lower than in similar studies. We think that one of 
the main reasons for this discrepancy may be the local 
climate in which the study was conducted. Yazd's 
climate is hot and dry. Mite (as a common allergen in 
other areas) is less common in areas with dry climates. 
Different results can also be due to differences in 
sample size and study design. There are several pieces 
of evidence in favor of medical treatment in AHT and 
OME.13-15 In a study by S. Cengel et al, 122 children 
with AHT and/or OME received intranasal 
mometasone or without any treatment in the control 
group. The improvement in OME symptoms was 
significantly higher in the case group (42.2%) than in 
the control group (14.5%).
13
 Berlucchi et al evaluated 
the efficacy of intranasal Mometasone Furoate for AHT 
in 57 children. The adenoid size and severity of 
symptoms decreased in 21 patients (77.7%) of the 
treatment group. No improvement was found in the 
placebo group.14 In another survey conducted by 
Solmaz et al, they evaluated the effect of topical 
mometasone on the adenoid volume in 75 patients with 
AHT. The adenoid volume decreased significantly after 
treatment with mometasone (p<0.0001), compared to 
the control group (p=0.3125).
15
 In our study, similar to 
other studies, the severity of symptoms decreased in 
most patients (80%) who were treated with intranasal 
corticosteroids. In patients with allergen sensitization 
response to treatment (100%) was higher than in 
patients without allergen sensitization (64%).  
The lack of a control group in our study did not 
allow us to make a comparison between treatment 
groups. We confirmed AHT based on findings of 
lateral cervical X-rays. Recent studies recommend the 
use of nasal endoscopy for this purpose. Larger sample 
sizes are recommended in future studies  
The accompaniment of AHT and OME with 
allergic disorders was common, with a higher rate of 
allergic rhinitis. Treatment with nasal corticosteroid 
and antihistamine in patients with AHT and OME who 
had atopic disorders was effective and this effect was 
greater in atopic patients who were sensitized to an 
allergen. A positive skin prick test may be a useful para 
clinical test to recognize AHT and OME patients with 
an atopic background whose response to intranasal 
corticosteroids and antihistamine would be better. 
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